Literature DB >> 22932264

Comparison of 2 contouring methods of bone marrow on CT and correlation with hematological toxicities in non-bone marrow-sparing pelvic intensity-modulated radiotherapy with concurrent cisplatin for cervical cancer.

Umesh Mahantshetty1, Rahul Krishnatry, Suresh Chaudhari, Aarti Kanaujia, Reena Engineer, Supriya Chopra, Shyamkishore Shrivastava.   

Abstract

OBJECTIVES: To compare volumes and dose volume histogram (DVH) parameters for bone marrow contours using 2 methods on computed tomography (CT) and correlation with grade 2 or higher hematological toxicity (HT) in patients with cervical cancer treated with non-bone marrow-sparing intensity-modulated radiotherapy (IMRT) with concurrent cisplatin.
MATERIALS AND METHODS: The planning CT scans of 47 patients prospectively enrolled and treated with IMRT arm of a phase 2 trial (NCT00193804) contoured for pelvic bone marrow in 2 sets; whole bone (WB), and freehand (FH) inner cavity of bone. Various subvolumes were made in each set--sacrum, ilium, ischium, lower pelvis, lumbosacral spine, sacrum, and whole pelvis--and compared for volume and DVH parameters (V(10), V(20), V(30), and V(40)) using paired t test. The hematological parameters during RT compiled from electronic database analyzed for higher than grade 2 (Radiation Therapy Oncology Group) HT and correlated with DVH parameters using log regression analysis (P < 0.05 significant).
RESULTS: The FH subvolumes were 25% to 30% of WB. The mean DVH parameters V(10), V(20), V(30), and V(40) for whole-pelvis FH and WB were 86.5%, 77.5%, 62.5%, and 40.5%; and 88%, 79.6%, 62.9%, and 40%, respectively. There was significant difference between the DVH parameters of 2 sets (P < 0.05) for all subvolumes except ischium V(20), sacrum V(10), and lumbosacral spine V(10). The leukopenia, neutropenia, anemia, and thrombocytopenia higher than grade 2 was seen in 53%, 29.8%, 65.9%, and 10.6%, respectively. The mean V(10) for whole pelvis was less than 90% for both sets. On both univariate and multivariate analyses, only FH whole pelvis V(40) more than or equal to 40% correlated with higher than grade 2 leukopenia (Mann-Whitney U test, P = 0.026) and neutropenia (P = 0.05) with odds ratio, 4 (95% confidence interval, 1.166-13.728; P = 0.028).
CONCLUSIONS: The FH bone marrow cavity volume is a better surrogate of active bone marrow on CT images and correlated with higher than grade 2 HT (V(40) >40%). Further prospective studies validating significance of high-dose effects and identifying correlation of bioimaging with CT contouring are warranted.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22932264     DOI: 10.1097/IGC.0b013e3182664b46

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  13 in total

Review 1.  The role of intensity modulated radiotherapy in gynecological radiotherapy: Present and future.

Authors:  Ana Fernandez-Ots; Juanita Crook
Journal:  Rep Pract Oncol Radiother       Date:  2013-10-03

2.  Radiotherapy dose escalation with concurrent chemotherapy in locally advanced cervix cancer is feasible.

Authors:  M W Hegazy; R I Mahmood; I A Al-Badawi; B Moftah; H AlHusaini
Journal:  Clin Transl Oncol       Date:  2015-07-10       Impact factor: 3.405

3.  Clinical and dosimetric factors associated with the development of hematologic toxicity in locally advanced cervical cancer treated with chemotherapy and 3D conformal radiotherapy.

Authors:  Miguel Ángel Souto-Del Bosque; Miguel Ángel Cervantes-Bonilla; Gerardo Del Carmen Palacios-Saucedo
Journal:  Rep Pract Oncol Radiother       Date:  2018-08-13

4.  Acute hematological toxicity during post-operative bowel sparing image-guided intensity modulated radiation with concurrent cisplatin.

Authors:  Shirley Lewis; Supriya Chopra; Pushpa Naga; Siddharth Pant; Epili Dandpani; Naveen Bharadwaj; Umesh Mahantshetty; Reena Engineer; Jamema Swamidas; Jaya Ghosh; Sudeep Gupta; Shyam Shrivastava
Journal:  Br J Radiol       Date:  2018-10-03       Impact factor: 3.039

5.  Conventional external beam volumes for cervical cancer: Are they adequate?

Authors:  Umesh Mahantshetty; Rahul Krishnatry
Journal:  South Asian J Cancer       Date:  2013-07

6.  How well do elderly patients with cervical cancer tolerate definitive radiochemotherapy using RapidArc? Results from an institutional audit comparing elderly versus younger patients.

Authors:  Santam Chakraborty; M Geetha; Sampada Dessai; Vijay M Patil
Journal:  Ecancermedicalscience       Date:  2014-11-20

7.  Early Clinical Outcomes, Patterns of Failure, and Acute Haematologic Toxicity of Image-Guided Volumetric Modulated Arc Therapy (IG-VMAT) in the Definitive Treatment of Locally Advanced Carcinoma Cervix.

Authors:  Irfan Ahmad; Kundan Singh Chufal; Irfan Bashir; Chandi Prasad Bhatt; Ram Bajpai; Lalit Sharma; Sandeep Rathour
Journal:  Clin Med Insights Oncol       Date:  2018-06-27

8.  Pelvic bone marrow sparing intensity modulated radiotherapy reduces the incidence of the hematologic toxicity of patients with cervical cancer receiving concurrent chemoradiotherapy: a single-center prospective randomized controlled trial.

Authors:  Jin Huang; Fei Gu; Tianlong Ji; Jing Zhao; Guang Li
Journal:  Radiat Oncol       Date:  2020-07-29       Impact factor: 3.481

9.  Dosimetric predictors of acute bone marrow toxicity in carcinoma cervix - experience from a tertiary cancer centre in India.

Authors:  Rohith Singareddy; Harjot Kaur Bajwa; Mahendra M Reddy; Alluri Krishnam Raju
Journal:  Rep Pract Oncol Radiother       Date:  2021-04-14

10.  Correlation between pelvic bone marrow radiation dose and acute hematological toxicity in cervical cancer patients treated with concurrent chemoradiation.

Authors:  T Kumar; A Schernberg; F Busato; M Laurans; I Fumagalli; I Dumas; E Deutsch; C Haie-Meder; C Chargari
Journal:  Cancer Manag Res       Date:  2019-07-08       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.